PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced three regulatory acceptances from the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) for Breyanzi® (lisocabtagene maraleucel). In the U.S., the FDA has accepted the company’s two supplemental Biologics License Applications (sBLA) for Breyanzi to expand into new indications to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and rela ...

The latest trading session saw Bristol Myers Squibb (BMY) ending at $49.87, denoting a +0.34% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.76%. On the other hand, the Dow registered a gain of 0.59%, and the technology-centric Nasdaq increased by 1.12%.Coming into today, shares of the biopharmaceutical company had lost 3.14% in the past month. In that same time, the Medical sector gained 1.57%, while the S&P 500 gained 2.5%.The investment community w ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of data from the Phase 3 CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) compared to intravenous (IV) Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy, demonstr ...

Healthcare stocks trudged through what was a terrible 2023 for the sector. While the S&P 500 rose by 24% during 2023, the healthcare sector managed paltry returns of 0.3%. Yet, hope springs eternal, particularly within the stock market, and investors are increasingly vocalizing their expectations for a 2024 rebound. Share prices throughout the sector remain muted, providing many targets for those hoping to capitalize on what they see as overly low valuations.Bargain hunters will have many choices throughout ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization approval of Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibod ...

Bristol-Myers Squibb Company (BMY) is scheduled to report fourth-quarter 2023 results on Feb 2, before market open.The company’s shares have lost 20.7% in the past six months compared with the industry's 0.3% growth.Image Source: Zacks Investment ResearchBristol-Myers beat earnings estimates in three of the last four quarters and missed once, the average surprise being 2.89%. In the previously reported quarter, the company beat estimates by 13.64%.Factors at PlayTotal revenues in the fourth quarter are like ...

PM Images It was another good week in the markets as the S&P 500 increased by 1.52% and the Nasdaq jumped 2.53%. The University of Michigan's consumer sentiment report increased to 78.8, which is the highest level since July of 2021. Technology led the markets higher as Taiwan Semiconductor (TSMC) announced a better-than-expected forecast that fueled the narrative around artificial intelligence. The U.S. economic data will be front and center next week as everyone will be looking for Q4 GDP growth estim ...

With the S&P 500 reaching new highs last week, investors appear to be taking an optimistic view of the overall stock market. However, not all stocks are participating in this rally. Some high-quality companies are still trading at beaten-down valuations, making them attractive value plays for investors. As monetary policy continues shifting in a more dovish direction, we could be at an inflection point where these value stocks start to regain their previous luster.That’s why I think now is an opportune time ...

After eight-straight monthly losses starting in April 2023, the shares of pharmaceutical concern Bristol-Meyers Squibb Co (NYSE:BMY) started to rebound in December, though were swiftly rejected by the 80-day moving average at the start of the year. Now, it looks like that bounce was indeed short-lived, as BMY is seeing even more pressure on the charts after its recent dip. According to Schaeffer's Senior Quantitative Analyst Rocky White, Bristol-Meyers stock is within one standard deviation of its 50-day an ...

The FDA has asked Gilead Sciences, Inc. (GILD) , Johnson & Johnson (JNJ) and Novartis (NVS) to add “boxed warning” to the labels of their chimeric antigen receptor (CAR) T-cell immunotherapies, per Reuters.The regulatory body sent letters to these companies stating that it had identified adverse events and clinical trial reports describing T-cell malignancies.We remind readers that in November 2023, the FDA announced that it was investigating the identified risk of T-cell malignancy in patients who received ...